USANA Health Sciences, Inc. provided consolidated earnings guidance for the fiscal year 2022. For the year, the company expects net sales to be in the range of $1.125 billion to $1.225 billion and diluted EPS to be in the range of $5.25 to $6.00.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.53 USD | +1.20% |
|
+0.04% | -15.06% |
05-07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
05-01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.06% | 857M | |
+12.97% | 8.27B | |
+3.37% | 7.47B | |
-15.13% | 5.23B | |
-9.87% | 3.62B | |
-19.61% | 3.26B | |
-12.98% | 1.22B | |
-30.67% | 1.06B | |
-10.43% | 861M | |
-4.54% | 858M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022